Loading clinical trials...

AVERT™ Clinical Trial for Contrast Media Volume Reduction and Incidence of CIN | Clinical Trials | Clareo Health

COMPLETEDNANCT01976299

AVERT™ Clinical Trial for Contrast Media Volume Reduction and Incidence of CIN

The Osprey Medical AVERT System is indicated to reduce contrast media (CM) exposure to the kidneys during percutaneous coronary procedures thereby reducing the risk of contrast induced nephropathy (CI...

Lead sponsor: Osprey Medical, Inc•37 U.S. locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Trial snapshot

StatusCOMPLETED

PhaseNA

Enrollment578

Start dateDec 2013

Last updatedFeb 28, 2017

Condition

Contrast Induced Nephropathy (CIN)

Locations shown

UCSD Medical Center

La Jolla, California

Long Beach CA VA Hospital

Long Beach, California

Kaiser Permanente Los Angeles Medical Center

Los Angeles, California

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: February 28, 2017Data synced to Clareo: May 17, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions